Muscarinic acetylcholine receptor X-ray structures: Potential implications for drug development

Current Opinion in Pharmacology

Volumn 16, Issue 1, 2014, Pages 24-30

  Kruse, Andrew C ^a   Hu, Jianxin ^b   Kobilka, Brian K ^a   Wess, Jürgen ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATROPINE; G PROTEIN COUPLED RECEPTOR; LY 2033298; LY 2119620; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; QUINUCLIDINYL BENZILATE; RHODOPSIN; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; SCOPOLAMINE DERIVATIVE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; BRONCHOCONSTRICTION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG MECHANISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REGULATORY MECHANISM; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM;

ANIMALS; CHOLINERGIC AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE;

EID: 84897874700     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.02.006     Document Type: Review

References (26)

1. P.J. Barnes Chapter 36. Pulmonary Pharmacology L.L. Brunton, B.A. Chabner, B.C. Knollmann, Goodman & Gilman's The Pharmacological Basis of Therapeutics edn 12 2011 McGraw-Hill New York http://wwwaccessmedicinecom/ resourceTOCaspx?resourceID=651
2. K.S. Buels, and A.D. Fryer Muscarinic receptor antagonists: effects on pulmonary function Handb Exp Pharmacol 208 2012 317 341
3. M. Cazzola, C.P. Page, L. Calzetta, and M.G. Matera Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 2012 450 504
4. F.R. Coulson, and A.D. Fryer Muscarinic acetylcholine receptors and airway diseases Pharmacol Ther 98 2003 59 69
5. J. Wess, R.M. Eglen, and D. Gautam Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development Nat Rev Drug Discov 6 2007 721 733
6. 3 muscarinic acetylcholine receptors FASEB J 18 2004 711 713
7. N. Struckmann, S. Schwering, S. Wiegand, A. Gschnell, M. Yamada, W. Kummer, J. Wess, and R.V. Haberberger Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice Mol Pharmacol 64 2003 1444 1451
8. K. Haga, A.C. Kruse, H. Asada, T. Yurugi-Kobayashi, M. Shiroishi, C. Zhang, W.I. Weis, T. Okada, B.K. Kobilka, T. Haga, and T. Kobayashi Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 482 2012 547 551
9. A.C. Kruse, J. Hu, A.C. Pan, D.H. Arlow, D.M. Rosenbaum, E. Rosemond, H.F. Green, T. Liu, P.S. Chae, and R.O. Dror et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482 2012 552 556
10. A.C. Kruse, A.M. Ring, A. Manglik, J. Hu, K. Hu, K. Eitel, H. Hübner, E. Pardon, C. Valant, and P.M. Sexton et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 504 2013 101 106
11. G.M. Keating Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease Drugs 72 2012 273 300
12. P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, and M. Pieper Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J Pharmacol Exp Ther 330 2009 660 668
13. P. Casarosa, T. Kiechle, P. Sieger, M. Pieper, and F. Gantner The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics J Pharmacol Exp Ther 333 2010 201 209
14. C.S. Tautermann, T. Kiechle, D. Seeliger, S. Diehl, E. Wex, R. Banholzer, F. Gantner, M.P. Pieper, and P. Casarosa Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor J Med Chem 56 2013 8746 8756
15. G.J. Digby, J.K. Shirey, and P.J. Conn Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol Biosyst 6 2010 1345 1354
16. M. De Amici, C. Dallanoce, U. Holzgrabe, C. Tränkle, and K. Mohr Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med Res Rev 30 2010 463 549
17. P. Keov, P.M. Sexton, and A. Christopoulos Allosteric modulation of G protein-coupled receptors: a pharmacological perspective Neuropharmacology 60 2011 24 35
18. J.R. Lane, P.M. Sexton, and A. Christopoulos Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol Sci 34 2013 59 66
19. 2 muscarinic acetylcholine receptor Drug Discov Today Technol 10 2013 e245 e252
20. J. Kloeckner, J. Schmitz, and U. Holzgrabe Convergent, short synthesis of the muscarinic superagonist iperoxo Tetrahedr Lett 51 2010 3470 3472
21. P. Scheerer, J.H. Park, P.W. Hildebrand, Y.J. Kim, N. Krauss, H.W. Choe, K.P. Hofmann, and O.P. Ernst Crystal structure of opsin in its G-protein-interacting conformation Nature 455 2008 497 502
22. H.W. Choe, Y.J. Kim, J.H. Park, T. Morizumi, E.F. Pai, N. Krauss, K.P. Hofmann, P. Scheerer, and O.P. Ernst Crystal structure of metarhodopsin II Nature 471 2011 651 655
23. 2 adrenoceptor Nature 469 2011 175 180
24. 2 adrenergic receptor-Gs protein complex Nature 477 2011 549 555
25. C. Valant, C.C. Felder, P.M. Sexton, and A. Christopoulos Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects Mol Pharmacol 81 2012 41 52
26. R.O. Dror, H.F. Green, C. Valant, D.W. Borhani, J.R. Valcourt, A.C. Pan, D.H. Arlow, M. Canals, J.R. Lane, and R. Rahmani et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 503 2013 295 299